MARKET

GNMSF

GNMSF

Genmab A/S
OTCPK
297.25
-10.75
-3.49%
Closed 12:50 02/17 EST
OPEN
310.00
PREV CLOSE
308.00
HIGH
310.00
LOW
297.25
VOLUME
25
TURNOVER
7.74K
52 WEEK HIGH
352.00
52 WEEK LOW
179.35
MARKET CAP
18.30B
P/E (TTM)
12.19
1D
5D
1M
3M
1Y
5Y
1D
Genmab GAAP EPS of $15.37, revenue of $3.72B misses by $50M; initiates FY26 outlook
Seeking Alpha · 7h ago
Genmab Announces Initiation of Share Buy-Back Program
Barchart · 21h ago
Genmab Files Annual Report with the U.S. Securities and Exchange Commission
Barchart · 1d ago
Harbor Small Cap Growth Fund Q4 2025 Portfolio Performance
Seeking Alpha · 01/30 03:30
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Barchart · 01/29 11:49
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2025
Barchart · 01/21 05:23
Genmab to Hold 2025 R&D Update and ASH Data Review Meeting
Barchart · 12/11/2025 01:00
Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma
Barchart · 12/07/2025 06:50
More
About GNMSF
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.

Webull offers Genmab A/S stock information, including OTCPK: GNMSF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GNMSF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GNMSF stock methods without spending real money on the virtual paper trading platform.